I'd really like to see some numbers on this.
From what I understand, there are far, far more marijuana users than there are heroin users -- like many orders of magnitude more. So, yeah, illegal marijuana growers could certainly switch to growing opium, but they're not going to magically get anywhere near the number of customers.
Here's a business insider article, and the data sources I used.
http://www.businessinsider.com/heroin-vs-opioid-overdose-sta...
https://www.cdc.gov/mmwr/volumes/65/wr/mm655051e1.htm http://www.newsweek.com/us-traffic-deaths-injuries-and-relat...
So certainly higher usage for marijuana, but definitely not "many orders of magnitude"
Supposedly a pharmacorp released a painkiller a few years ago thats supposed to last longer pr dose than then existing ones.
but when patients complained that they didn't work, the corporate advice to doctors was to up the pr pill dosage rather than advice the patients to take the pills more often (as that would make a lie of their marketing claims).
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3365767/
In contrast [with Ibogaine], all other known SERT inhibitors are competitive with substrate (28). These competitive inhibitors include several compounds that also inhibit the closely related dopamine and norepinephrine transporters
Does someone with enough knowledge to actually understand this paper want to chime in and maybe explain? It seems well-written, but reliant upon knowing, what, say, SERT and DAT are.
Edit: This other paper also came up: https://www.ncbi.nlm.nih.gov/pubmed/7568622
Substrate: the thing that's supposed to bind to something normally. SERT: transporter that pulls serotonin out of synapses back into the neuron that put them there in the first place. DAT: similar, but for dopamine and to some degree norepinephrine. Competitive inhibition: inhibition depends on whether the intended substrate for a site is present—the drug and substrate interfere with each other competitively. Non-competitive inhibition: the drug inhibits the function of a site even if the intended substrate is already bound to it.
As to how any of this explains or refutes claims ibogaine short-circuits withdrawal, I dunno. Feels a bit like trying to explain JavaScript in terms of quantum mechanics. Both these papers are evaluating the drug's interaction with neurons, not the drug's effect or non-effect on addiction.
https://www.washingtonpost.com/news/wonk/wp/2017/03/09/gop-h...
Is that a labelled use? Because most physicians are restricted or prevented from prescribing drugs for "off label" use.
Wrong. You have no idea what you're talking about: https://en.wikipedia.org/wiki/Off-label_use#United_States
Besides methadone there's also buprenorphine and Suboxone, which are opiate replacements. Not the kind of thing you take to get high, something to use to taper off so the withdrawals aren't so intense.
Heroin abuse is a big problem that's only going to get bigger in the US. A lot of folks got addicted back when Purdue was pushing Oxycontin, and now that it's harder for them to obtain they've switched to the cheaper and more potent stuff.
Doctors need to know how to treat withdrawal, period. There are lots of options besides methadone (which has it's own nightmare withdrawal if stopped abruptly, and which lasts three times longer than heroin withdrawal).